https://www.fiercepharma.com/pharma/analysts-prescription-big-pharma-take-ma-small-doses
Both Mangal and Henry believe M&A activity will be brisk this year. Biotech valuations have declined since their peak but have been rebounding in recent months, providing some impetus for dealmakers to strike.
Another critical factor is the $200 billion revenue hit the industry will take by way of patent losses over the next decade.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |